"Also, I didn't realise GILD was fairly active in acquiring cell based therapy companies. They bought out Kite for $11.9B in 2017. Will add GILD to the list of potential acquirers of MSB. They have been under pressure to buy new lines of revenue for the last 7-8 years since their hepatitis cures reached peak sales. I was a holder some time ago."
They don't have deep enough pockets
Cell Therapy News/Articles, page-5006
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
0.015(1.33%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.19 | $1.13 | $7.803M | 6.763M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 5737 | 2 |
View Market Depth
| Last trade - 15.59pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.15 |
Change
0.015 ( 2.46 %) |
||||
| Open | High | Low | Volume | ||
| $1.16 | $1.19 | $1.13 | 1229288 | ||
| Last updated 15.59pm 22/05/2024 ? | |||||
| MSB (ASX) Chart |